Anika Therapeutics Inc (NAS:ANIK)
$ 16.9601 0.6601 (4.05%) Market Cap: 248.39 Mil Enterprise Value: 201.25 Mil PE Ratio: 0 PB Ratio: 1.39 GF Score: 80/100

Anika Therapeutics Inc Presenting at UBS Global Healthcare Virtual Conference Transcript

May 25, 2021 / 12:00PM GMT
Release Date Price: $43.78 (-0.23%)
Xuyang Li
UBS Investment Bank, Research Division - Equity Research Analyst of Medical Supplies & Devices

Okay. Great. Good morning, everyone. Thanks for joining us on the second day of the UBS Healthcare Conference. My name is Young Li from UBS' U.S. Medical Devices and Devices Team (sic) [U. S. Medical Supplies and Devices Team].

For this session, I'm pleased to be joined by management from Anika Therapeutics, including Dr. Cheryl Blanchard, President and CEO; and Mike Levitz, EVP, CFO and Treasurer.

Just to kick things off for this session, we're going to have some slides from Anika, followed by Q&A. (Operator Instructions)

So Cheryl and Mike, thanks so much for joining us. Really appreciate your time today. I'll turn over the floor to you.

Cheryl R. Blanchard
Anika Therapeutics, Inc. - President, CEO & Director

Great. Thanks, Young, and thanks to UBS for the invitation to present today and have some time for Q&A so that we can tell Anika's story. Let me just remind everybody of our safe harbor statement, our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot